Event-free survival (SE) of the 198 children with high-risk non-B ALL treated in the AIEOP-ALL95 study according to subgroups defined by eligibility criteria in hierarchical order.

See Table 2. Patients (pts) resistant to protocol Ia (Res Ia), regardless of the remaining features, and so on for the subsequent subgroups (ie, patients with t(9;22) translocation, infants with t(4;11) or CD10⁻, PPR-only patients (these were poor responders to prednisone but free of all previous features).